Welcome to our dedicated page for Arch Biopartners news (Ticker: ACHFF), a resource for investors and traders seeking the latest updates and insights on Arch Biopartners stock.
Arch Biopartners Inc. (ACHFF) generates news primarily around its kidney-focused drug development programs, clinical trial milestones, and intellectual property expansions. As a late-stage clinical trial company, Arch regularly reports progress on Phase II studies targeting acute kidney injury (AKI) and updates on its emerging chronic kidney disease (CKD) platform.
News releases frequently cover developments in the LSALT peptide program, including site activations, ethics approvals, and patient recruitment in the international, multicenter Phase II trial for cardiac surgery-associated acute kidney injury (CS-AKI). These updates highlight new hospital sites joining the study in Canada and Turkey, dosing milestones, and design refinements approved by regulators.
Investors and observers also see detailed announcements on cilastatin, Arch’s repurposed DPEP1 inhibitor for drug toxin-related AKI. Coverage includes good manufacturing practice (GMP) production of the first stand-alone cilastatin drug product, funding awards to the investigator-led PONTIAK Phase II trial in Alberta, and the start of patient recruitment to evaluate cilastatin’s ability to prevent nephrotoxin-induced AKI.
More recently, Arch has reported on its acquisition of a pre-clinical IL-32 CKD platform through the purchase of Lipdro Therapeutics Inc. News in this area focuses on newly filed composition and method-of-use patents, the scientific rationale linking IL-32 to diabetic CKD, and the addition of new scientific leadership to guide the CKD program.
Readers following Arch Biopartners’ news can expect regular updates on trial enrollment, regulatory and ethics approvals, collaborations with academic medical centers, patent activity, and scientific publications that support the company’s nephrology-focused pipeline. This news flow provides ongoing insight into how Arch is advancing its drug candidates for acute and chronic kidney diseases.
Arch Biopartners has announced that its lead drug candidate, LSALT Peptide, will enter the Canadian Treatments for COVID-19 (CATCO) trial. This clinical study will involve 320 patients across 65 hospitals in Canada and is aligned with the WHO’s SOLIDARITY trial. The decision follows positive Phase II trial results, indicating more ventilation-free days for LSALT patients compared to placebo. The trial will assess LSALT’s efficacy in treating acute organ inflammation in COVID-19 patients, supported by the Sunnybrook Research Institute and Health Canada approvals.
Arch Biopartners has announced ongoing analysis of its Phase II trial results for the LSALT peptide (Metablok), aimed at preventing organ inflammation due to COVID-19. The trial involved multiple clinical sites and evaluated the drug's effectiveness against ARDS and AKI. Recruitment was completed in May, with data reconciliation finalized in June, allowing analysis to start in July. The company plans to disclose results after peer review and aims to use the findings to inform a future Phase III program.
Arch's pipeline includes LSALT peptide as a DPEP-1 inhibitor, with patent protection for cilastatin to prevent acute kidney injury.
Arch Biopartners Inc. announced the awarding of a CIHR Team Grant worth $750,000 to its scientists for research on the LSALT peptide (Metablok) to prevent inflammation in chronic kidney and lung diseases. This study will advance understanding of DPEP-1, an adhesion receptor for neutrophils, and its role in organ inflammation during acute illnesses like AKI and ARDS. The funds will aid pre-clinical studies and optimize clinical trial designs targeting DPEP-1, alongside supporting ongoing drug development within Arch's portfolio.
Arch Biopartners Inc. has filed a new provisional patent application to protect antibody drug candidates targeting inflammation mediated by dipeptidase-1 (DPEP-1) in the lungs, liver, and kidneys. This filing enhances its patent portfolio and introduces a novel class of therapeutics alongside existing peptide candidates. The company also concludes patient recruitment for its Phase II trial of LSALT peptide (Metablok), which aims to prevent organ inflammation in COVID-19 patients. The trial's results will inform the design of future Phase III studies.
Arch Biopartners Inc. (ACHFF) has completed enrollment for its Phase II trial of Metablok (LSALT Peptide), aimed at treating acute lung and kidney injuries caused by inflammation in severe COVID-19 cases. A total of 65 patients participated, with results expected in July 2021. The trial is designed to assess Metablok's efficacy in preventing organ inflammation that can lead to severe complications in COVID-19 patients. Positive outcomes may inform a Phase III program with a larger patient cohort.
Arch Biopartners has entered an exclusive global license agreement with Telara Pharma to develop cilastatin, a small-molecule drug aimed at preventing acute kidney injury (AKI). This collaboration unifies existing patents and supports a new Phase II trial targeting AKI, a condition affecting 10-15% of hospitalized patients, with a market valued over $20 billion. Cilastatin, previously used in combination with imipenem, inhibits dipeptidase-1 (DPEP-1), an adhesion receptor linked to inflammation. Arch's Metablok is also in trials addressing similar pathways.
Arch Biopartners Inc. (OTCQB: ACHFF) received approval from the Turkish Ministry of Health to double patient recruitment for its Phase II trial of LSALT peptide (Metablok), targeting acute lung and kidney injuries linked to severe COVID-19 cases. The trial now allows for 40 patients in Turkey, with the first 20 having completed treatment. The ongoing surge in COVID-19 cases in Turkey, exceeding 32,000 daily infections, emphasizes the trial's urgency. As of now, 46 patients have been recruited across North America and Turkey, aiming to demonstrate Metablok's efficacy in preventing organ inflammation.
Arch Biopartners Inc. (ACHFF) has received a No Objection Letter from Health Canada regarding protocol amendments for its Phase II trial of LSALT peptide (Metablok), which targets organ inflammation in severe COVID-19 cases. Changes include lowering the minimum patient age from 45 to 18 and simplifying the treatment regimen. These modifications aim to enhance enrollment and patient care in the study. The amended protocol will be submitted to the U.S. FDA and Turkish Ministry of Health. The trial is crucial for evaluating Metablok's effectiveness against acute lung and kidney injuries in COVID-19 patients.
Arch Biopartners Inc. announced the publication of a paper by Dr. Daniel Hassett, demonstrating that AB569 effectively kills multi-drug resistant Acinetobacter baumannii and Acinetobacter spp. pathogens in combat wounds. These bacteria pose significant infection risks to military personnel. Arch is exploring human trials for AB569 as a topical treatment for wound infections, diabetic wounds, and potentially as a solution for urinary tract and lung infections. The company emphasizes the urgent need for innovative antimicrobial solutions amid rising antibiotic resistance.
Arch Biopartners Inc. announced that the Peter Lougheed Center in Calgary has joined its Phase II trial for the LSALT peptide (Metablok), aimed at preventing acute lung and kidney injuries in COVID-19 patients. This center is the second in Calgary to participate, following the University of Calgary's Foothills Medical Centre. Patient enrollment is ongoing in the U.S., while Turkish sites await health ministry approval for expansion. The trial aims to evaluate LSALT peptide's efficacy and safety in reducing organ inflammation associated with severe COVID-19 outcomes.